• Careers
  • ZOLL Patient Management Network Login
  • About Us
    •
  • For Patients

    For Patients

    Learn about your ZOLL medical product

  • For Medical Professionals

    For Medical Professionals

    Explore our portfolio of solutions for cardiac patient management

    Solutions Overview
  • Support
    •
  • For Patients

    For Patients

  • For Medical Professionals

    For Medical Professionals

  • Support
  • Careers
  • ZOLL Patient Management Network Login
  • About Us
  • Country

    Country

    •
  • For Medical Professionals
  • LifeVest
    • zoll-life-vest

    20+ years of clinical evidence. 1M+ patients protected.

    The world’s most used, studied, and proven wearable cardioverter defibrillator (WCD).

    LEARN MORE CONTACT US
    man wearing LifeVest sitting outside accompanied with young child
  • Outcomes
  • How LifeVest Works
  • Guidelines
  • Actionable Insights
  • FAQs
  • Patient Support & Engagement

    • The only WCD proven to reduce mortality with RCT data

    As seen in the 2020 VEST per-protocol analysis, patients that wore LifeVest® realized significant mortality reductions in the first 90 days after a cardiac event.¹

    EXPLORE LIFEVEST OUTCOMES
    graph depicting LifeVest Data: 75% relative risk reduction in death, any cause graph displaying LifeVest data: 62% relative risk reduction in arrhythmic death

    20+ years of evidence across 1M+ patients
    90 percent one-year survival infographic
    LifeVest Clinical Evidence 23.4 hours/day median daily wear time graphic
    LifeVest Clinical Evidence Zero median false alarms at 90 days infographic

    How LifeVest works: Performance meets comfort

    How does the LifeVest Wearable Defibrillator work?

    The LifeVest wearable cardioverter defibrillator (WCD) protects patients at risk of sudden cardiac death (SCD), when a patient’s condition is changing and permanent SCD risk has not been established.

    LifeVest is designed to detect VT/VF and, if needed, automatically deliver a treatment shock to restore normal heart rhythm.
    Chart displaying an Example Detection and Treatment sequence of the LifeVest wearable cardioverter defibrillator for VF

    Timely defibrillation with an AI-enhanced algorithm

    The LifeVest TruVector™ detection algorithm uses AI-enhanced Advanced Arrhythmia Detection (AArD) technology to quickly and accurately detect VT/VF (at a default VT threshold of 150bpm).

    In a typical situation, the entire event, from detection to treatment, occurs in about one minute.

    The next generation LifeVest Garment

    Continuous optimization of the LifeVest design has led to a median real-world Wear Time® of 23.4 hours/day.3

    Patients rate the newest LifeVest garment as even more comfortable, compared to the previous version.5

    Explore more innovations for better outcomes

     

    LifeVest WCD guideline recommendations
    Guideline Recommendations Chart for Wearable Cardioverter Defibrillator

    AHA/ACC/HRS guidelines

    Guidelines from the American Heart Association (AHA)/American College of Cardiology (ACC)/Heart Rhythm Society (HRS) include recommended use of the wearable cardioverter defibrillator (WCD) for a wide range of patients at risk for SCD, including post-MI, post-PCI, and NICM patients.6 

    SCD MANAGEMENT GUIDELINES

    Actionable insights for better outcomes
    ZOLL Patient Management Network ICONS

    1 in 14 patients experience an arrhythmia while wearing LifeVest.⁷

    Through ZOLL Patient Management Network, LifeVest provides actionable insights about your patient during cardiac recovery to help you achieve a range of treatment goals, including:

    • Optimization of medical therapy
    • Assess progress during recovery
    • More productive telehealth and follow-up
    • Timely clinical interventions, from ablation to ICD selection
    EXPLORE LIFEVEST INSIGHTS

    Frequently Asked Questions

    How does LifeVest work?

    LifeVest is designed to detect certain life-threatening rapid heart rhythms and, if needed, automatically deliver a treatment shock to restore normal heart rhythm. Timely defibrillation is the single most important factor to save a patient that is experiencing a rapid, life-threatening arrhythmia. A treatment shock must be delivered within a few minutes after an event to be effective; with each passing minute, a patient’s chances of survival drops 10 percent. LifeVest does not require bystander intervention. In a typical situation, the entire event, from detecting a life-threatening rapid heartbeat to automatically delivering a shock, occurs in about one minute.

    What type of patient is the LifeVest WCD appropriate for?

    LifeVest is prescribed by a physician as part of the continuum of care for patients at risk for SCD. LifeVest is used for a wide range of patient conditions or situations, including following a heart attack, or before or after bypass surgery or stent placement, as well as for those with cardiomyopathy or congestive heart failure that places them at particular risk for SCD.

    Is LifeVest covered by insurance?

    LifeVest is covered by most health plans in the United States, including commercial, state, and

    • Primary prevention (EF ≤35% and MI, NICM, or other DCM), including:
      • After recent MI (Coverage during the 40-day ICD waiting period)
      • Before and after CABG or PTCA (Coverage during the 90-day ICD waiting period)
      • Listed for cardiac transplant
      • Recently diagnosed nonischemic cardiomyopathy (Coverage during the 3 to 9-month ICD waiting period)
      • NYHA Class IV heart failure
      • Terminal disease with life expectancy of less than 1 year
    • ICD indications when patient condition delays or prohibits ICD implantation
    • ICD explanation

    Patient support & engagement
    Infographic stating that 100% of Medicare Part B plans cover LifeVest and 95% of people in the U.S. have in-network coverage. ZOLL offers a range of financial plans and programs for uninsured and underinsured patients

    Access & coverage

    ZOLL is committed to providing patients with easy access to LifeVest, regardless of insurance coverage or income level. We’ve spent 20+ years building relationships and programs to ensure patients can receive the protection they need.
    ORDERING & COVERAGE
    Woman looking at phone, which is displaying LifeVest patient app data

    Patient education & support

    In-person, remote, and digital options ensure that you and your patients are supported every step of the way:

    • The largest team of patient service representatives with patient care backgrounds for in-person training
    • 24/7 multilingual support at 1-800-543-3267
    • The LifeVest patient app provides patients with tips for wearing and interacting with LifeVest, and allows them to review their usage time and activity as they work towards their recovery goals.
    ENGLISH PATIENT RESOURCES SPANISH PATIENT RESOURCES

    1. Olgin JE, Lee BK, Vittinghoff E, et al. Impact of wearable cardioverter-defibrillator compliance on outcomes in the VEST trial: As-treated and per-protocol analyses. J Cardiovasc Electrophysiol 2020;1–10. https://doi.org/10.1111/jce.14404.
    2. Kutyifa V, Moss A, Klein H, et al. One-Year Follow-Up of the Prospective Registry of Patients Using the Wearable Defibrillator (WEARIT-II Registry). Pacing Clin Electrophysiol. 2018;1–7. https://doi.org/10.1111/pace.13448
    3. Data on file, 90d0258_a01. 2021 Commercial Compliance Analysis.
    4. Arkles J, Delaughter C, D’Souza B. A novel artificial intelligence based algorithm to reduce wearable cardioverter-defibrillator alarms. J Interv Cardiac Electrophysiol. 2023. https://doi.org/10.1007/s10840-023-01497-w
    5. Data on file, 20c1184_a01. Garment Comparative Wear Test.
    6. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force on clinical practices guidelines and the Heart Rhythm Society. Circulation. 2017; CIR.0000000000000549.
    7. Kutyifa V, Moss AJ, Klein H, et al. Use of the wearable cardioverter defibrillator in high-risk cardiac patients: Data from the prospective registry of patients using the wearable cardioverter defibrillator (WEARIT-II Registry). Circulation 2015;132(17):1613–1619.

    Contact a Product Expert

    ZOLL is ready to assist you in meeting your care goals. The team that has protected 1M+ LifeVest patients over 20+ years now provides a suite of solutions. Connect with an expert for personalized support.

    CONTACT US     Medical professionals looking at a tablet in hospital hallway